FTO and acute myeloid leukemia: For example, the highly selective and potent catalytic inhibitor of FTO (FB23‐2) exhibits significant repression of AML maintenance and prolonged the survival of AML recipients in vivo.[32] However, there has been little research on the effect of m6A in T‐ALL.